Although MI-CLAIM provides a strong strategic framework for the evaluation of a broad range of ML applications, in our opinion, the evaluation of the validity and potential biases of ML studies in specific clinical use cases of pediatric DM, such as insulin bolus calculation or hypoglycemia detection from various physiological signals, would require more specific technical guidance, preferably from the medical profession, who provides the data and ultimately uses the results for clinical decision-making. This evidence concerns the gene INS and diabetes mellitus.